– 28 May 2024
Annual General Meeting of Ipsen S.A. held on 28 May 2024
– 27 May 2022
ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different…
– 08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
– 18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in…
– 13 February 2023
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line…
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 139 Press Releases
–
07 May 2025
07 May 2025
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
PARIS, FRANCE, 7 May 2025 Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking presentations on IQIRVO® (elafibranor) during the European Association for the Study of the Liver congress.
–
06 May 2025
06 May 2025
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership…
–
24 April 2025
24 April 2025
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver (EASL) congress as…
–
16 April 2025
16 April 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS,…
–
08 April 2025
08 April 2025
Ipsen publishes its 2024 Universal Registration Document
Ipsen publishes its 2024 Universal Registration Document
Your dedicated contacts
-
Ioana Piscociu
Senior Manager, Media Relations
-
Stay updated